S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Zomedica Stock Forecast, Price & News

-0.09 (-4.81 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $1.78
50-Day Range
MA: $0.18
52-Week Range
Now: $1.78
Volume121.25 million shs
Average Volume217.43 million shs
Market Capitalization$1.00 billion
P/E RatioN/A
Dividend YieldN/A
Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Zomedica logo


4 Hot Penny Stocks For March 2021 (ZOM)
March 1, 2021 |  marketbeat.com
See More Headlines

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$1.00 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

0.94 out of 5 stars

Medical Sector

1073rd out of 1,972 stocks

Drug Manufacturers - Specialty & Generic Industry

19th out of 61 stocks

Analyst Opinion: 1.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.09 (-4.81 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZOM News and Ratings via Email

Sign-up to receive the latest news and ratings for ZOM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Zomedica (NYSEAMERICAN:ZOM) Frequently Asked Questions

Is Zomedica a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zomedica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zomedica stock.
View analyst ratings for Zomedica
or view top-rated stocks.

What stocks does MarketBeat like better than Zomedica?

Wall Street analysts have given Zomedica a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zomedica wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zomedica's next earnings date?

Zomedica is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Zomedica

How were Zomedica's earnings last quarter?

Zomedica Corp. (NYSEAMERICAN:ZOM) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter.
View Zomedica's earnings history

How has Zomedica's stock been impacted by Coronavirus (COVID-19)?

Zomedica's stock was trading at $0.2078 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZOM stock has increased by 756.6% and is now trading at $1.78.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ZOM?

1 analysts have issued 1 year price objectives for Zomedica's shares. Their forecasts range from $0.30 to $0.30. On average, they anticipate Zomedica's stock price to reach $0.30 in the next year. This suggests that the stock has a possible downside of 83.1%.
View analysts' price targets for Zomedica
or view top-rated stocks among Wall Street analysts.

Who are Zomedica's key executives?

Zomedica's management team includes the following people:
  • Dr. Stephanie Laine Morley D.V.M., DVM, Pres & Chief Medical Officer (Age 46, Pay $263.37k)
  • Mr. Bruk Herbst, Chief Commercial Officer (Age 52)
  • Mr. Robert Cohen, CEO & Director (Age 63)
  • Ms. Ann Marie Cotter CPA, CFO & Sec. (Age 51)
  • Mr. Michael Schilk, VP of Sales
  • Mr. David Eaton, VP of Marketing
  • Dr. William Carpenter MacArthur, Consultant (Age 58)
  • Mr. Robert W. DiMarzo, Consultant (Age 64)

Who are some of Zomedica's key competitors?

What is Zomedica's stock symbol?

Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."

How do I buy shares of Zomedica?

Shares of ZOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zomedica's stock price today?

One share of ZOM stock can currently be purchased for approximately $1.78.

How much money does Zomedica make?

Zomedica has a market capitalization of $1.00 billion.

How many employees does Zomedica have?

Zomedica employs 28 workers across the globe.

What is Zomedica's official website?

The official website for Zomedica is www.zomedica.com.

How can I contact Zomedica?

The company can be reached via phone at 734-369-2555.

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.